Canaccord raises Taysha Gene Therapies price target on trial progress.
Share this article
Corporate
Score 35
Bullish
Canaccord raises Taysha Gene Therapies price target on trial progress
Apr 06, 2026 11:57 UTC
TAYSA
Short term
Related Articles
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.